3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
41
Carcinoma, Renal Cell
32
Neuroendocrine Tumors
15
Neoplasms
12
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Carcinoma
7
Tuberous Sclerosis
6
Kidney Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoid Tumor
5
Lymphoma
4
Adenoma, Islet Cell
4
Stomach Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
3
Lymphangioleiomyomatosis
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Angiomyolipoma
3
Adenocarcinoma
3
von Hippel-Lindau Disease
2
Triple Negative Breast Neoplasms
2
Seizures
2
Neuroectodermal Tumors, Primitive
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Interventions
pembrolizumab
1
Ocoxin
1
Everolimus
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Stomach Diseases
×
Everolimus
×
Clear all
NCT00879333
2015-11-03
GRANITE-1
Novartis
Phase 3
Completed
656 enrolled
15 charts